The pharmaceutical major, Ranbaxy has agreed to pay around $40 million, in connection with its reported pricing data to Texas Medicaid for certain drugs. "Ranbaxy believes that it fully complied with all relevant laws, however the company settled the matter to avoid any further distraction and uncertainty of continued litigation with the state of Texas," the company said.